We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Minor Modification to Botox May Boost Binding and Improve Safety
News

Minor Modification to Botox May Boost Binding and Improve Safety

Minor Modification to Botox May Boost Binding and Improve Safety
News

Minor Modification to Botox May Boost Binding and Improve Safety

Modified BoNT/B (blue) is modeled onto membranes through anchoring with its two receptors (yellow and red), showing that the two tryptophan residues interact with membranes. Credit: From Fig 6D, Yin et al, 2020
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Minor Modification to Botox May Boost Binding and Improve Safety"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Botulinum toxin (BoNT) is used for a range of applications from treating chronic pain to reducing the appearance of wrinkles, but when injected it can diffuse into the surrounding tissue and give rise to adverse effects. A new study publishing March 17 in the open-access journal PLOS Biology by Linxiang Yin and Min Dong of Boston Children's Hospital, USA and colleagues shows that a subtle modification of an FDA-approved form of BoNT enhances binding to the nerve cells and improves the drug's potency and safety.

Botulinum toxin (BoNT) is produced by the Clostridium botulinum bacterium in seven serotypes, BoNT/A through G. All work in a similar way: after attaching to nerves near their junction with muscles (the neuromuscular junction), a portion of the toxin crosses the nerve's membrane to prevent release of neurotransmitter and thereby paralyze the muscle. A commercial form of BoNT/A is approved for clinical treatment of various forms of muscle overactivity as well as cosmetic reduction of wrinkles, while a commercial form of BoNT/B is approved for a movement disorder called cervical dystonia.

BoNTs have two sites that recognise two separate receptors at the nerve terminal. Previous work has shown that several BoNTs including BoNT/B have an extended loop along the amino acid chain between the two receptor binding sites. Structural modeling suggested that if this loop contains hydrophobic (oily) amino acids it could interact with lipids in the nerve cell membrane, providing a third point of attachment and so increasing binding efficiency. These hydrophobic amino acids are present in the loop of several BoNTs, but not in BoNT/B.

Because potency is increased and adverse effects decreased by stronger binding, the authors investigated whether adding hydrophobic amino acids to this lipid-binding loop in BoNT/B might improve binding of the toxin to the nerve terminal. They showed that replacing just two amino acids in the loop with hydrophobic tryptophans did in fact enhance binding in vitro. They then produced a new BoNT/B containing this mutation plus a pair of mutations that had been previously shown to enhance binding to one of the two BoNT/B receptors, and demonstrated that this engineered toxin was more potent than the approved form of BoNT/B in a standard mouse paralysis assay. In addition, the new toxin caused less reduction in body weight, an effect consistent with a reduction in diffusion of the toxin away from the injection site.

"Our study shows that the changes introduced into BoNT/B can increase the therapeutic potential of the toxin and reduce adverse effects," Dong said. "Engineering the botulinum toxins in this way may provide a new avenue for improving safety and clinical benefit from these drugs."

Reference: Linxiang Yin, et al. (2020). Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. PLOS Biology. DOI: 10.1371/journal.pbio.3000618

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement